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Nitric oxide (NO) is one of the 10 smallest molecules found in nature. It is a simple gaseous free radical
whose predominant functions is that of a messenger through cGMP. In mammals, NO is synthesized by the
enzyme nitric oxide synthase (NOS) of which there are three isoforms. Neuronal (nNOS, NOS1) and en-
dothelial (eNOS, NOS3) are constitutive calcium-dependent forms of the enzyme that regulate neural and
vascular function respectively. The third isoform (iNOS, NOS2), is calcium-independent and is inducible. In
many tumors, iNOS expression is high, however, the role of iNOS during tumor development is very
complex and quite perplexing, with both promoting and inhibiting actions having been described. This
review will aim to summarize the dual actions of iNOS-derived NO showing that the microenvironment of
the tumor is a contributing factor to these observations and ultimately to cellular outcomes.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Nitric oxide (NO) is a free radical gasotransmitter that regulates
various biological functions in the body. After it was identiﬁed in
the 1980s as a vasoactive small molecule, the cardiovascular ac-
tivities of NO were more notable mainly related to its vascular
relaxation function, and to its anti-thrombotic and anti-in-
ﬂammatory effects [1,2]. Besides blood ﬂow regulation, NO in-
volvement is recognized in other physiological functions such as
neurotransmission, immune-response facilitation and in anti-
pathogenic response [3–5].
The production of NO in cells under normal physiological
conditions occurs by the conversion of L-arginine to L-citrulline by
the enzyme nitric oxide synthase (NOS). There are three isoforms
of NOS: neuronal NO synthase (nNOS, also known as NOS1), in-
ducible NO synthase (iNOS or NOS2) and endothelial NO synthase
(eNOS or NOS3) [3,6] (Fig. 1). The category called constitutive NOS
(cNOS) includes both nNOS and eNOS and when activated only
produce nanomolar concentrations of NO for seconds or minutes.
However, iNOS the inducible isoform generates higher amounts of
NO, in the micromolar range and for longer intervals such as for
hours or days [7]. Both cNOS members depend on increases in
calcium ion concentrations for activity; hence, produce low
amounts of NO for short durations, whereas iNOS is calcium-in-
dependent. In general, the expression levels of iNOS in tissues is
also a measure of NO generated in that tissue or its surrounding
environment [6].
NO was mainly viewed as an oncogenic molecule for several
years. However, the biological functions of the NOS enzymes and
the activities of NO have been disseminated over the years with a
ﬁner eye. This was possible partly due to pharmacological success
of NO releasing compounds against heart disease and also to
beneﬁcial effects of these compounds when combined with che-
motherapy against certain cancers [3,4]. Among the effects of NOFig. 1. Biosynthesis of NO and its mechanism of action. NO is produced by three
nitric oxide synthase (NOS) isoforms neuronal, endothelial, and inducible (nNOS,
eNOS, and iNOS) that catalyze the oxidation of L-arginine to L-citrulline. NO acti-
vates the enzyme sGC to increase cGMP production that has downstream signaling
effects. NO also has biological action by modiﬁcation of protein through
S-nitrosylation.in cancer, it is now evident that NO plays important roles in var-
ious stages of carcinogenesis such as DNA damage, oncogene ac-
tivation, inhibition of DNA repair enzymes and tumor suppressor
genes, and the modulation of apoptosis and metastasis [8–11].
Anti-tumor effects of NO produced by the immune-defense system
were demonstrated to function against tumors of different human
origins in animal models [12], while implications of pro-tumor
effects of NO were made by association with expression of en-
zymes that produce NO in tumor cells in progressing tumors and
metastasized tissue [13]. Over the years a dual role of NO in cancer
has been acknowledged [9,14,15] and studied with more mo-
mentum to dissect the mechanisms leading to these two activities
with respect to tumorigenesis [9,14].
1.1. Basic mechanism of action of NO
In order to appreciate the dual role of NO, its signaling pathway
deserves some elaboration. Two major pathways are at play re-
garding signaling mechansims of NO. One is cGMP-dependent
(NO–sGC–cGMP pathway) and the other is cGMP-independent,
which is also referred to as the NO oxidative pathway. For the NO–
sGC–cGMP signaling pathway in blood vessels, L-arginine is con-
verted by NOS to produce NO which diffuses enzymes to in the
lumen and in the walls. In leukocyctes, NO derived from NOS may
diffuse across the plasma membrane and cytoplasm. NO reacts
with the active site of soluble guanylate cyclase (sGC) and pro-
duces cyclic GMP (cGMP). cGMP activates cGMP-dependent Pro-
tein Kinase G (PKG), which phosphorylates multiple substrates
[16]. The other two major downstream elements that may also be
activated are cGMP dependent gated ion channels, and cGMP
dependent phosphodiesterase [16]. In platelets, activation of the
cGMP dependent kinase phosphorylates a variety of substrates,
and is involved in platelet adhesion and aggregation [17]. In gen-
eral, an increase in cGMP leads to smooth muscle relaxation
(Fig. 1), vasorelaxation and decrease of platelet aggregation [17,18].
The cGMP-independent pathway occurs most commonly
through modiﬁcation of proteins by S-nitrosylation of the cycteine
residues [19–21] (Fig. 1). Such post translational modiﬁcation also
affects transcriptional activity by alteration of DNA binding of the
protein, notably the transcription factor NF-κB which loses ability
to bind DNA due to such modiﬁcations [22,23]. Hypoxia-inducible
factor-1 (HIF-1) estrogen receptor and NF-κB are also redox sen-
sitive transcription factors that are regulated by S-nitrosylation
[24]. Signaling events regulated by S-nitrosylation may lead to
either progression or inhibition of cancer. S-nitrosylation of NF-κB
and matrix metalloproteinase 9 (MMP9) promotes cell death
whereas S-nitrosylation of caspase-3, caspase-9, and c-Jun
N-terminal kinase prevents activity and inhibits apoptosis [23].
Death receptors were also found to be regulated by for example,
nitrosylation of death receptor DR4 and Fas promotes apoptosis
via the death-inducing signal complex [25,26].
NO reacts with oxygen radicals to form peroxynitrite which is a
strong oxidative and nitrosative agent, resulting in direct ni-
trosylation or nitrosation or nitration of signaling proteins. Ni-
trosative signaling in cancer cells is known to contribute to more
proliferation and metastasis, and resistance to therapy and
therefore, poor outcome of treatment [27]. On the other hand,
apoptotic and necrotic cell death can occur by peroxynitrite via
lipid peroxidation, cysteine oxidation, and also by protein ni-
trosylation [28,29].2. More than a tale of two concentrations
The presence of NOS isoforms and their ability to produce
different levels of NO was the basis for the concept that different
Fig. 2. NO modulates various cellular activities by altering multiple pathways. Abbrv: PI3K-AKT: Phosphatidylinositol-3-Kinase and Protein Kinase B; MAPK: Mitogen-
activated protein kinase; ERK: Extracellular signal-regulated kinase; JNK: c-Jun N-terminal protein kinase; VEGF: Vascular endothelial growth factor; HIF: Hypoxia inducible
factor; COX2: Cytochrome Oxidase subunit 2; IL8: Interleukin 8; PGE2: Prostaglandin E2; Cyt c: Cytochrome c; Bcl-2: B-cell lymphoma 2; HSP70: Heat Shock protein 70;
RKIP: Raf kinase inhibitor protein; EMT: Epithelial Mesenchymal transition; Bcl-xl: B-cell lymphoma-extra large XIAP: X-linked inhibitor of apoptosis protein; MMP: Ma-
trixmetalloproteinase; cGMP: Cyclic guanosine monophosphate; NO: nitric oxide.
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The physiological function of NO is dependent primarily on its
concentration. At low concentrations, NO acts as a signaling mo-
lecule regulating smooth muscle relaxation and blood ﬂow, neu-
rotransmission, platelet activity, iron homeostasis, cell curvival
and proliferation whereas at high concentrations it is believed to
modulate immune-mediated anti-tumor activities [32,33] (Fig. 2).
Considering a cancer cell, the cellular outcome is based on addi-
tional factors for response such as the cell or tumor type, duration
of exposure, NO ﬂux, and immune and vascular cells. Therefore,
the update in NO and cancer biology is that the overall effect of NO
is an interplay of its activities emanating from its amount from the
tumor and from its microenvironment.
A low concentration of NO of less than 100 nM prevents certain
cell types from apoptosis, and thereby favor tumorigenesis and
progression [34,35]. A sustained low efﬂux of NO derived from
eNOS stimulates the proliferation of the endothelail cells [36]. The
low efﬂux is estimated to be approximately 1–10 nmol/L [31] that
lead to such endothelial cell response. Based on several reports of
NO measurements in tissues and from exogenous NO donors, the
concentrations of NO have been established as low dose (50–
100 nM), high dose (400–1000 nM) or intermediate dose (100–
400 nM) [37,38]. High concentrations of NO, more than 500 nM,
may be pro-apoptotic, producing cytotoxicity and antitumor ac-
tivity [33,39]. High NO levels that produced cytotoxic effects on
tumor cells are derived from macrophages, neutrophils, en-
dothelial cells, hepatocytes, cardiac myocytes and chondrocytes
[40–43].
Many exogenous NO donors have been used in obtaining dif-
ferent levels of NO. For example, DETA-NONOate produced high
amounts of NO inhibited epithelial-mesenchymal transition (EMT)
and invasion of human prostate metastatic cells [44]. Metastatic
inhibition was also proposed to occur at high NO levels [45].
Therefore, high levels of NO relating to antitumor and also anti-
metastatic properties have raised hopes for therapies.
NO levels and their molecular inﬂuences are complicated bythreshold amounts. Some exogenous donors have provided accu-
rate measurements of threshold NO exposure and distinct effects
on cells. Using spermineNONOate low NO doses of 10–300 nM
were obtained in MCF-7 breast cancer cells [46] which induced
proliferative events such as ERK phosphorylation and HIF-1α
(hypoxia induced factor 1α) accumulation resulting in tumor
proliferation and differentiation [46]. Further p53 phosphorylation
occurrs at high doses of NO (above 300 nM), generally known to
be associated with apoptosis induction. Therefore, in addition to
high and low doses, different threshold levels of NO are required
for activation or stabilization of key proteins involved in
carcinogenesis.
Reactive oxygen species (ROS) also inﬂuence threshold NO le-
vels within the tumor microenvironment. ROS may modulate
signaling by NO as was observed in both tumor and endothelial
cells [39]. Another complication is the development of NO re-
sistant cells through low yet continuous exposure to NO. Such
tumor cells show cellular adaptation and enhanced survival by
altered threshold levels [47]. NO may also form reactive nitrogen
species (RNS) through interaction with the superoxide radical and
may cause DNA damage and genotoxicity [48]. In an inﬂammoroty
process, NO and RNS may therefore stimulate carcinogenesis.
Based on in vitro NO release by donors and their in vivo re-
presenation of NO/RNS levels at the sites of tumors, the con-
centration ranges of NO by NO-donors have also been proposed to
be divided into the following two ranges: Moderate concetntration
range (100–350 μmol/L) and high concentration range (500–
1000 μmol/L) [49]. The normal NO levels are generally below the
50 nmol/L level. The cellular responses of the moderate cconcen-
tration range includes increases in cell proliferation and genomic
instability, and decrease in apoptosis and DNA repair [50,51]. The
outcomes for the high concentration range include decreases in
cell proliferation and increase in apoptosis, DNA damage and sti-
mulation of DNA-damage signaling pathways leading to ATM/ATR-
dependent p53 phosphorylation [52] (Fig. 2).
Fig. 3. The transcription factor NF-κB is central to iNOS regulation. LPS, IL-1β, TNF-
α, and IL-6 have been shown to induce iNOS, whereas glucocorticoids (GlC),
transforming growth factor-β1 (TGFβ1), antioxidants (e.g. pyrrolidine dithiocarba-
mate, PDTC) and inhibitors of phosphatidylcholine-speciﬁc phospholipase (PC-PLC)
have been shown to inhibit iNOS expression by inhibiting NF-κB activation.
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Since presence of three different NOS enzymes in cells are a
reﬂection of levels of NO produced, reports have demonstrated
that the relationship of NO to the dynamics of tumor growth is
linked to certain determining features. These are; the expression
patterns of NOS isoforms in various types of cells, the amount of
NO produced by each isoform in the cell type including the
duration, and the chemical interactions of NOS-derived NO in the
cell [53]. Among the three NOS enzymes in mammalian systems,
iNOS stands apart as it generates more NO than the constitutive
members nNOS or eNOS [7,54], is expressed after cytokine ex-
posure, and more speciﬁcally modulates important tumor related
processes such as malingnant transformation, angiogenesis, and
metastasis [7,54]. iNOS-derived NO and its tumorigenic or tu-
moricidal activities are dual roles of considerable interest that are
debated in cancer biology [34,55]. Anti-tumor effects of iNOS have
been examined by many researchers despite the volume of tumor
promoting reports of NO. The current understanding is that during
the phases of tumor growth, the epithelial cells of the growing
tumor have tumorigenic properties via iNOS activity while the
environmental stroma community, for example, tumor-associated
macrophages provide tumoricidal activities also via iNOS, and a
competition sets in and dynamics alter with time [56]. When these
dynamics are elucidated to a ﬁner detail, therapies may be tailored
for the appropriate activity of NO.
3.1. iNOS gene, polymorphisms and basic regulation
In order to understand the role of iNOS in proliferative or anti-
tumor kinetics, a brief background of iNOS gene and iNOS reg-
ulation is presented ﬁrst. The human iNOS gene is located on
chromosome 17q11.2-q12. There are several sequences with high
homology to the iNOS genes in the human genome [57]. Different
polymorphisms have been described in the sequence of the hu-
man iNOS promoter [58,59]. Single nucleotide polymorphism of
the iNOS gene (NOS2A Ser608Leu) caused a two-fold risk increase
for B- and T-cell non-Hodgkin lymphoma and also for the diffuse
large B-cell and follicular lymphomas [60,61]. A penta nucleotide
repeat polymorphism -CCTTT (n)- that occurs in the human iNOS
promoter at position – 2.5 kb with a median number of 12 CCTTTT-
repeats, has been correlated with severity of human diseases in-
cluding gastric cancer [62], glaucoma [63] and urothelial carcino-
ma [64,65].
One advance in the understanding of gene expression regula-
tion involves epigenetics. In particular, DNA methylation at the C-5
positions of cytosine in the CpG dinucleotide occurs as a common
epigenetic mechanism leading to gene silencing. In human al-
veolar macrophages and monocytes CpG motifs near the tran-
scription start site of the iNOS promoter have been shown to be
methylated, which means it is an epigenetically silenced iNOS
gene [66]. Histone modiﬁcations were also found to be low at the
iNOS promoter region suggesting low activity of the gene [66].
Regarding non-genetic regulatory mechansims, iNOS is pri-
marily regulated at the expressional level by inﬂammatory cyto-
kines (TNF-α; IL-1β IFN-γ), lipopolysaccharide endotoxin, hypoxia
and oxidative stress [67,68] and more recently, by heat schock
protein Hsp70 which may function like a cytokine [69] (Fig. 3).
Transcriptional and post-transcriptional mechanisms resulting in
the induction of iNOS expression are found to vary in different cell
types or species. The most important intracellular signal trans-
duction pathways are the NF-κB and JAK-STAT pathways [70–73].
Inhibition of iNOS expression by numerous agents, such as glu-
cocorticoids, TGF-β1 and antioxidants have been shown to result
from inhibition of NF-κB and STAT-1α activation [74–77] (Fig. 3).
In addition, MAPK pathway contributes to iNOS gene expressioninvolving the activation of transcription factors such as AP1, ATF2,
cAMP-responsive elements, NF-κB, and the transcription factors
from the Ets family [34,72,78]. Post-transcriptional regulation of
iNOS gene expression predominantly occurs via mechanisms that
inﬂuence iNOS mRNA stability [59].4. Tumor iNOS and NO
The roles of NO relating to apoptosis, cell cycle, tumor pro-
gression, angiogenesis and metastasis, are currently veiwed at the
host end and tumor end since NO was found to be actively asso-
ciated with tumors as well as the tumor environment, for example
the vasculature cells and other stromal cells. In earlier studies in
cultured cells high levels of NO that were generated by iNOS
transfection in tumor cell lines produced a cytostatic or growth
inhibitory effects [79–81], whereas in animal models, iNOS over-
expression produced pro-tumor or anti-tumor effects on tumor
growth, depending on the tumor microenvironment and the tu-
mor type [82–84]. The tumor microenvironment includes stromal
cells such as cells of the immune system and vascular tissue, and
NO was established to be a component for their activities [84].
Overall, the effect of NO depends on the expression level of iNOS,
duration and timing of NO delivery, the microenvironment, the
genetic background and the cell type.
4.1. Overexpression of iNOS and anti-tumor activity
Overexpression of iNOS and concomittant changes on cancer
cell kinetics were demosntrated to be anti-cancer in potential
according to several in vitro and in vivo studies. Prostate cancer
cells DU145 and PC3, and colon cancer HT-29 cell produced en-
hanced amounts of NO upon overexpression of iNOS by gene
transfer, which increased these cells' sensitivity to cisplatin-in-
duced cell death [85] or to radiation therapy [86]. In a mouse
model of thyroid cancer, iNOS overexpression inhibited tumor-
igenesis [87]. In animal models of ﬁbrosarcoma, tumor progression
slowed down upon expression of iNOS via gene transfer demon-
strating potential of tumor growth inhibition by iNOS-derived NO.
Introduction of iNOS in conjunction with cytokines IFN-γ in
prostate cancer cells also inhibited growth of the cells [88]. iNOS
expressing pancreatic cancer cells did not produce tumors or
metastases in xenograft mouse models due to NO upregulation
and apoptosis [89]. Overexpression by means of other delivery
forms of iNOS also produced anti-tumor results. In xenograft
models of human colon and ovarian cancers, delivery of iNOS
expressing cells by microencapsulation increased apoptosis of
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duced slowly progressing tumors and fewer lung metastases than
control mice transfected with iNOS-negative retrovirus [90]. In
contrast, reducing iNOS expression by NOS inhibitors in MDA-MB-
231 and T47D estrogen receptor (ER)-negative breast cancer cells
led to increase in motility and loss of adhesion implying a role of
NO in inhibititng the progression of breast cancers [27].
Induction of iNOS derived NO is believed to occur in photo-
dynamic therapy, which is a recent area for treatment of cuta-
neous tumors. This procedure induces iNOS as a cytoprotective
response. It is envisaged that combination of NO-inhibitors and
photodynamic therapy may improve its clinical use [91].
4.2. Bystander anti-tumor effect
Bystander effect referes to a non-targeted response and gen-
erally holds signiﬁfcance with respect to radiation therapy. How-
ever, in gene therapy, it refers to the ability of the transfected cells
to transfer death signals to neighboring tumor cells [92]. iNOS
gene delivery by designer biomimetic vector and iNOS nano-
particles were found to overexpress iNOS and produce cytotoxicity
and cell death in ZR-75-1 breast cancer cells, coupled with killing
of bystander cells [93]. Similarly, radiation-induced bystander ef-
fects and cell killing are mediated through an iNOS-derived NO
[94].
4.3. The mechanisms of anti-tumor effects: cytotoxicity and
apoptosis
Typical mechanisms in NO-mediated apoptosis include caspase
activation, chromatin condensation, and DNA fragmentation
[95,96]. At the molecular level, high concentrations of NO derived
from iNOS in macrophages induce p53 phosphorylation resulting
in endotheial cell growth arrest, and higher concentrations and
prolonged exposure time induce cell death [37]. Prolonged pro-
duction of NO has been associated with the release of cytochrome
c from the mitochondria, activation of caspase, modulation of anti-
apototic Bcl-2 proteins, and increase in p53 expression [97]
(Fig. 2). Alternatively, NO may induce the expression of DNA-de-
pendent protein kinase in DNA repair that confers protection
against oxidative and nitrosative stress [98]. A recent study has
reported that one of the underlying mechanisms by which NO-
mediated NF-κB inhibition suppresses tumor cell resistance and
metastasis is through inhibition of the downstream targets Snail
and the transcription factor Yin Yang 1 (YY1) and induction of Raf-
1 kinase inhibitor protein (RKIP) [99] (Fig. 2). Finally, evidence
indicating that endothelial-cell derived NO mediates the elimina-
tion of disseminated tumor cells is increasing. For example, it has
been shown that endothelial cell-produced NO had a cytotoxic
effect on disseminating tumor cells [100]. A bystander signaling
mechanism which depends on ROS or iNOS derived NO has also
been examined to produce cell killing effects [49], however it may
depend on the cell situation and environment of the tumor cell.
4.4. iNOS expression and pro-tumor activity
iNOS derived NO have been associated with many tumors and in
their progression into metastatsis. iNOS positivity has been reported
consistently in human cancers at a variety of sites, including the lung
[101] prostate [102], breast [103], bladder [104], oral cavity, esophagus
[105] and colon [106]. In each single case, the effects of NO have to be
interpreted with regard to the microenvironment of the tumor. In-
creased iNOS activity has been positively correlated with the degree of
malignancy in gynecological tumors [80], gastric cancer, squamous cell
carcinoma, hepatocellular carcinoma, melanoma and leukemia [107],
while high iNOS expression is associated with favorable prognoses inovarian [108] and lung cancers [109]. Osteosarcoma of the jaw in
patients was associated with over expression of iNOS as deduced by
immunohistochemical analysis [110]. Similarly, oral carcinomas and
oral hard tissue sarcoma in patients were also associated with iNOS
expression. Interesteingly, soft tissue oral sarcomas from this study
were negative for iNOS expression [111] and iNOS expression in car-
cinomas was higher than in sarcomas. In women with estrogen re-
ceptor (ER)-negative breast tumors, iNOS expression is an in-
dependent marker for prognosis. iNOS positivity related with angio-
genesis of tumors, accumulations of p53 mutations and EGFR activa-
tion [27]. In other clinical studies of gastric cancer, iNOS correlated
with tumor progression and has potential to be of prognostic value
[112]. Low levels of expression of iNOS produced tumors in the pan-
creas and led to liver metastasis and ascites in mice models while
higher levels of iNOS expression did not lead to metastasis. When
iNOS expression was inhibited, it promoted distant liver metastasis in
these mice [113]. Nitric oxide is propososed to remodel the cytoske-
leton and lead to metastasis of lung cancer cells with evidence of in-
creased expression of iNOS in these cells.
4.5. Bystander pro-tumor effect and cell situation
NO has context-dependent effects which may be compiled as
‘cell situation’, and when viewed in totality, may affect neoplastic
transformation. iNOS derived NO and RNS in cells lead to genomic
instability and tumorigenesis in the microenvoronment through a
proposed “ﬁeld effect” where bystander cells are affected. This
effect was used to explain BRCA1 downregulation in bystander
MCF-10A breast epithelial cells cocultured with iNOS-stimulated
macrophages [50]. Further, radiation induced bystander effects
include a role of iNOS which appear to be either pro- or anti-tumor
depending on the cell situation. Induction of iNOS derived NO is
believed to occur in photodynamic therapy, which is a recent area
for treatment of cutaneous tumors. This procedure induces iNOS.
In animal models of photodynamic therapy, resistance to cell
killing has been reported due to increased NO derived from iNOS
from breast and prostate tumors [114]. In human prostate cancer
cells, there was enhanced proliferation and migration of the
photostressed surviving cells, and increased invasion was due to
NO-mediated activation of matrix metalloproteinase-9 (MMP-9),
an ECM component [114–116]. Therefore pro-survival inﬂuences
affecting surviving cells after photo-killing imply that iNOS in-
duction is a cell situation consideration, and may be a secondary
response to an altered status.
4.6. Cell situation and iNOS/NO effect
Protective or cytotoxic effects depend on the cells situation. In
tumor cell lines with wild type p53, DNA damage by NO and/or
modiﬁcation through nitrosative stresses, as in some transformed
cells, induces the accumulation of p53 resulting in apotosis. It was
found that p53 binds to the promoter region of the iNOS gene to
inhibit protein iNOS expression and further generation of NO [117].
On the other hand, NO also stabilizes p53 leading to apoptosis
[118], for example; induction of iNOS expression in tumor cells
with wild type p53 resulted in reduced tumor growth [119]. Fur-
ther, when examined in a p53 negative host, a study showed that
iNOS-derived NO suppresses lymphomagenesis by promoting
apoptosis and decreasing tumor cell proliferation [120].
Apoptosis induction mediated by NO via iNOS induction also
occurs in colorectal [121] and pancreatic cancer cells [122] by IL-2-
activated killer lymphocytes upon stimulation with inﬂammatory
cytokines IFN-γ and TNF-α. In general the process was found to
require high NO output with a high concentration in the tumor
microenvironment.
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NO promotes migration by reduced cell adhesion, and therefore
promotes invasion. This occurs through inhibition of integrin ex-
pression. In particular NO was found to speciﬁcally inhibit
α2β1integrin-mediated platelet adhesion to immobilized collagen
[123]. Other molecular events leading to induction of iNOS ex-
pression and generation of NO include activation of integrin
α9β1and src tyrosine kinase activity which enhanced cell migra-
tion [124]. In addititon, NO was found to modulate the matrix
metalloproteinase-8 (MMP-8) or procollagense expression and its
activity, and therefore affected tumor cell invasion (Fig. 2). NO has
been implicated in the activation pathways of MMP-1, -2, -3, -8, -9
[125–127]. NO inhibits the progression of breast cancers since
down-regulation of NOS with NOS inhibitors in MDA-MB-231 and
T47D cells was found to lead to increase in motility and loss of
adhesion [128].
4.8. Pro-tumor effects of stromal iNOS/NO
Besides the tumor cells, the stromal cells of the host produce
NO also. These stromal host cells in the tumor micro-environment
constitute immune cells such as macrophages, ﬁbroblasts and
vascular cells, and include the basement membrane and extra-
cellular matrix as well. There is a constant and dynamic interplay
between the tumor cells and the stroma immune cells, which
changes according to the change in conditions. In early events of
tumorigenesis, macrophages generate high concentrations of NO/
RNS to initiate tumor cell apoptosis and destroy emerging trans-
formed cells. When or as the tumor escapes the immune system
and grows, macrophages are reprogramed by the tumor micro-
environment to support the tumor. Low amounts of NO/RNS are
pro-angiogenic and support tumor growth and metastasis by in-
ducing growth factors VEGF and matrix metalloproteinases. Stu-
dies in gastric cancer (GC) patients found iNOS expression was
associated with distant metastasis, vascular and lymph node de-
velopment. Approximately 54% of the GC tumors displayed iNOS
expression associated with tumor progression and thereby has the
potential to indicate poor prognosis in GC patients [129]. In an-
other study, iNOS and COX-2 were induced in gastric cancer cells
that were co-cultured with gastric stromal ﬁbroblasts and in-
volved interaction of the IL-6-STAT3 pathway from the ﬁbroblasts
to promote tumor growth [130]. p53 status of tumors also plays an
important role. Inactivated p53 in ﬁbroblasts may also contribute
to iNOS-mediated tumor growth. For example, in a more recent
report of co-culture studies with p53 deﬁcient mouse embryonic
ﬁbroblasts (MEF) and rectal polyploid carcinoma CMT93 cells, the
MEFs produced more iNOS and COX-2 expression, and iNOS-de-
rived NO led to promotion of tumor growth [131]. iNOS may also
serve as a biomarker for metastasis of lung cancer. In lung cancer
patients with bone metastasis, the circulating metastatic cells
were found to have increased iNOS expression contributing to
increase in Epithelial Cell Adhesion Molecule (EpCAM) which is
associated with metastasis due to reduced cell-cell-adhesion [101].
Breast mammography of high density ﬁbroblasts are proposed to
produce a stress response and make ﬁbroblasts behave like mac-
rophages based on increased iNOS derived NO production and JNK1
stress kinase signals, leading to an inﬂammatory process and pro-
moting breast cancer [132]. iNOS expression in tumor parenchyma
and stroma in gastric cancer patients showed positive correlation
with gastric carcinogenesis, tumor lymphangiogenesis and lym-
phatic metastases [133]. Treatment with a Toll-like receptor agonist
imiquimod in iNOS-knockout mice that were implanted with tumor
cells improved tumor suppression compared to control wild-type
mice, and led to a better survival rate. Combination of imiquimod
and iNOS inhibitor produced similar results [134].4.9. Anti-tumor effects of stromal iNOS/NO
Anti-tumor activity emanating from stromal iNOS was also de-
monstrated over the years. An increase in iNOS and iNOS-mediated
NO release in stromal macrophages or ﬁbroblasts in the tumor en-
vironment was associated with anti-tumor activity in pancreatic can-
cer [135] and in LPS stimulated macrophages [136]. The interplay and
dynamics of tumor-iNOS expression and host-iNOS were also con-
sidered, where in wild type and iNOS –/– mice responded differently
to iNOS-negative tumor cells; the murine ﬁbrosarcomas in the iNOS
–/–mice increased at faster rate than in the wild type host [137]. iNOS
were also induced by Lipid A and interleukin 10 which inhibited tu-
morigenesis in colon and breast cancers in rodent models [138,139].
Delivery of liposomes containing lipopeptides suppressed murine
sarcoma hepatic metastasis by induction of iNOS and NO generation
[140]. In human ovarian cancer models, an interesting observationwas
that only NO-producing macrophages exhibited antitumor activity.
IFN-β-transfected tumor cells which were injected into the peritoneal
cavity of nude mice produced no tumors compared to control cell
injections, and were found to stimulate high NO levels in the murine
macrophages [141]. Therefore, host iNOS or stromal iNOS may provide
anti-tumor activity.
4.10. Stromal iNOS and cell situation considerations
iNOS from stromal cells may not be indicative of any one effect.
A factor that complicates host versus tumor iNOS performance is
NO sensitivity of the tumor cells. Different tumor types may have
differential NO sensitivity. It was demonstrated that host iNOS
deletion increased metastatic tumor growth of M5076 ovarian
sarcomas in the lung, whereas in other examples of iNOS–/– mice,
a reduced metastasis of B16–BL6 melanomas occurred [142]. A
tissue speciﬁc sensitivity is hypothesized where in M5076 cells are
sensitive to macrophage-induced NO, whereas B16–BL6 cells are
insensitive, implying that host iNOS favors tumor progression of
B16–BL6 cells. Another contributing factor affecting tumor out-
come is tissue type. The pathways regulating iNOS expression are
different depending on cell type [143]. In murine breast carcino-
ma, tumor cell-iNOS decreases the metastatic development
whereas stromal cell-iNOS increased metastasis [144]. In contrast,
in human cervical intraepithelial neoplasias increased iNOS in the
cervical stroma was associated with poor response to IFN-alpha 2B
immunotherapy [145]. Platelets are required for the vascular en-
dothelium adhesion to tumor cells. Platelet aggregation prevents
tumor cell removal by immunological attack [146]. NO from tumor
cells prevent platelet aggregation. The antitumor actions include
loss of malignancy due to inhibition of platelet aggregation
through a cGMP-dependent mechanism. A metastatic human
colorectal carcinoma cell line has lower iNOS activity but higher
platelet aggregation compared with a non-metastatic tumor line
that is derived from the same patient [147].
Regarding immune suppression activity, NO inhibits the pro-
duction of IL-12 frommacrophages and dendritic cells [148]. It was
believed that NO modulates differentiation of T helper cells and
therefore controls the T cell response [149–151] and later it was
shown that iNOS from activated T cells selectively modulate T cell
differentiation [152].5. NO molecular pathways and signaling
A collective view of the NO related pathways from the studies
reviewed here needs to be highlighted at this point. Increased
production of NO may promote tumor progression and metastasis
by diect induction of tumor cells proliferation, migration and in-
vasion and indirectly through the expression of angiogenic factors
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MAPK, such as ERK, JNK/SAPK and p38 kinases [153,154]. A special
mention of NFκB is necessary since NF-κB pathway which is a pro-
survival mechanism has been found to be a central player and
indeed, it is activated in over 50% of all cancers [155,156]. Pro-
motion of metastasis by NF-κB has been reported through in-
creased epithelial to mesenchymal transition [157,158]. In breast
cancer cells, other pathways are activated, for example phospha-
tidyinositol 3-kinase (PI3K/Akt), c-Myc and HIF [159,160]. Others
have reported NO activation in β-catenin transcriptional regula-
tion in osteocytes [161] and colorectal cancer cells [162], and in
models of colitis [163]. Regarding low level exposure to NO, tumor
cells show cellular adaptation and through enhanced survival,
particularly by producing IL-10, TGF-β and PGE2 [47].
5.1. Pharmacological inducers of iNOS and cell fate
Statins are cholestererol lowering agents that inhibit HMG-CoA
reductase. These agents have been shown to have tumoricidal and
apoptotic activity that is mediated by iNOS induction [164]. Epi-
demiological studies have suggested that statins have anti-cancer
activity against many cancers including breast carcinoma [165].
Among the various studies, post-menopausal breast cancer pa-
tients using statins had signiﬁcant beneﬁt when individual classes
of statin therapy were used, although not for all classes combined
[166]. In MCF-7 breast cancer cells, two representative agents
simvastatin and ﬂuvastatin induced iNOS mRNA and protein ex-
pression, reduced proliferation and induced apoptosis in these
cells. In ER-negative and metastatic triple negative cancer cells,
ﬂuvatstatin produced anti-proliferative and anti-invasive effects
also by increasing iNOS-derived NO [167]. In contrast pitavastatin
reduced iNOS mRNA expression and supprressed intestinal polyp
development in APC Min mice models of colon carcinogenesis
[168]. Considering the fact that statins are used for cholesterol
management for more than two decades, it is important to note
that there is no data to suggest that patients with statin regimen
are at a greater risk of developing any type of cancer. At the same
time, iNOS overexpression or its inhibition are not sole indicators
of tumor fate.
Cancer chemopreventive agents that have anti-tumor activity
have been examined for iNOS induction and inhibition. Interest-
ingly, in accordance with a dual role of iNOS, compounds that
induce iNOS are cancer preventive and compounds that inhibit
iNOS are also cancer preventive. Induction of iNOS-derived NO
production by fenretinide, a retinamide derivative of vitamin A, is
necessary for growth inhibition and promotion of apoptosis of
metastatic breast cancer cells. The amount of NO related directly to
the instensity of these repsonses. In contrast, reduced iNOS ex-
pression by liposomal fenretinide was obtained in animal models
of hepatocarcinogenesis [169,170]. The well known chemother-
apeutic agent 5-ﬂurouracil (5-FU) induced iNOS derived NO and
induced apoptosis in liver cancer cells. Agents that induced NO
formation such as L-arginine improved the sensitivity of the cells
to 5-FU [171]. Other pharmacological agents that are NO-donors
and are chemopreventive agents, such as the NO-donating Non-
steriodal antiinﬂammatory drugs (NO-NSAIDs), for example NO-
donating aspirin, have demonstrated reduction in cytokine-in-
duced iNOS expression associated with growth inhibition of HT-29
colorectal cancer cells [172,173]. The same ﬁnding was corrobo-
rated in azoxymethane-induced colonic tumors in rats where NO
donating-aspirin or -ibuprofen inhibited iNOS expressiona and
activity, and reduced tumor incidence and multiplicity [174].
It is clear that iNOS and NO affects many types of cells and at
various stages. To explain many of these phenomenon from cell
and animal models and in human cancers, more studies on the
interplay between tumor cells, immune cells, tumor-associatedmacrophages, endothelial and epithelial cells mediated by iNOS in
cancer progression and metastasis are needed.
From a speculative point of view it begins to appear that iNOS
is likely an adaptive response to cellular stresses and a mimic of
certain cell situations. At the cost of appearing simplistic, it may be
envisaged that iNOS has similar role as the heat shock protein
Hsp70 which is stress inducible with similar dual roles in cancer,
such as promoting tumor cells to survive and regulating antitumor
immunity. iNOS may cross talk with Hsp70 [69], and HSP70 and
iNOS expressions reﬂect a collective response affecting cell fate
[175]. Perhaps iNOS may be given a similar status as Hsp70.6. Conclusions and perspectives
During past two decades or so much has been written about
the dual nature of NO, which strongly suggests a concentration-
dependent relationship between NO expression and biological
response. This phenomenon is well accepted in pharmacology.
What has been the cornerstone of much debate is the role of iNOS
in cancer. Does its expression mean that iNOS-derived NO is car-
cinogenic or anti-carcinogenic? The current thinking based on
observations that iNOS expression is high in a number of tumors
and that this correlates with poor survival, has led to the conclu-
sion that induction of this NOS isoform may somehow be related
to tumor genesis or that its expression may be used as marker for
not so favorable outcomes. However, we believe that such a con-
clusion is still not warranted as in totality, it appears that the dual
role of iNOS is strongly inﬂuenced by the cell situation and is
environment dependent, with either induction or inhibition of
iNOS having anti-cancer potential based on tumor and cell types.
We belive that any approaches to iNOS based therapy against
cancer may need to be cell situation based and needs a lot more
directed studies.Grant support
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